HIV/AIDS

Proof-of-principle results for HIV drug candidate released

Published in Proteomics Weekly, December 20th, 2004

Panacos Pharmaceuticals, Inc., announced positive preliminary results from a proof-of-principle phase I/II clinical trial of the company's lead HIV drug candidate, PA-457.

In that study, PA-457 was administered as a single oral dose to HIV-infected patients who were not on other therapy, in order to determine the pharmacokinetics and antiviral effect of the compound. Several different dose levels were tested in addition to placebo and the level of virus in the plasma, known as the viral load, was measured before and at intervals after treatment in each patient. A significant reduction in viral load, of up to approximately 0.7 log10, was seen in patients receiving the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2004-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry